Harpoon Therapeutics, Inc. financial data

Symbol
HARP on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Boulevard, Suite 400, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 144 % -20.6%
Debt-to-equity 1.85 K % +683%
Return On Equity -895 % -351%
Return On Assets -46 % +22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9 M shares -49%
Common Stock, Shares, Outstanding 4.11 M shares -87.6%
Entity Public Float 26.8 M USD -89.8%
Common Stock, Value, Issued 1 K USD -75%
Weighted Average Number of Shares Outstanding, Basic 3.95 M shares +19.4%
Weighted Average Number of Shares Outstanding, Diluted 3.95 M shares +19.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 37.3 M USD +16.1%
Research and Development Expense 58.6 M USD -29.5%
General and Administrative Expense 16.1 M USD -20.3%
Operating Income (Loss) -39.1 M USD +45%
Net Income (Loss) Attributable to Parent -30.5 M USD +57%
Earnings Per Share, Basic 1.89 USD/shares +86.9%
Earnings Per Share, Diluted 1.89 USD/shares +86.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7 M USD -64.8%
Marketable Securities, Current 13.9 M USD -11.8%
Cash, Cash Equivalents, and Short-term Investments 31.6 M USD -52.2%
Assets, Current 34.3 M USD -50.4%
Property, Plant and Equipment, Net 3.53 M USD -55.5%
Operating Lease, Right-of-Use Asset 8.86 M USD +57.6%
Other Assets, Noncurrent 898 K USD +10.7%
Assets 47.6 M USD -43%
Accounts Payable, Current 3.44 M USD +30.1%
Employee-related Liabilities, Current 2.68 M USD -32%
Accrued Liabilities, Current 11.7 M USD -25.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 18.1 M USD -66.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 11.5 M USD +26.1%
Liabilities 43 M USD -35.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1 K USD
Retained Earnings (Accumulated Deficit) -365 M USD -9.13%
Stockholders' Equity Attributable to Parent 4.54 M USD -73.1%
Liabilities and Equity 47.6 M USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.3 M USD +23.6%
Net Cash Provided by (Used in) Financing Activities 26.6 M USD +3107%
Net Cash Provided by (Used in) Investing Activities 2.44 M USD -92%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 4.11 M shares -87.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9 M USD -64.8%
Deferred Tax Assets, Valuation Allowance 73.9 M USD +16.5%
Deferred Tax Assets, Gross 76.2 M USD +17.7%
Operating Lease, Liability 14.5 M USD +32.2%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.5 M USD +57%
Lessee, Operating Lease, Liability, to be Paid 18 M USD +33.9%
Property, Plant and Equipment, Gross 3.85 M USD -75.6%
Operating Lease, Liability, Current 2.97 M USD +62.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.35 M USD +54%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.23 M USD +54.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.47 M USD +41.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.49 M USD +54.1%
Deferred Tax Assets, Operating Loss Carryforwards 50.9 M USD +9.97%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 20.8 M USD +37.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.79 M USD -7.44%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 662 K USD +9.6%
Deferred Tax Assets, Net of Valuation Allowance 2.28 M USD +76%
Share-based Payment Arrangement, Expense 5.49 M USD -46.9%
Interest Expense 2.05 M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%